Lidocaine vaginal gel - Juniper Pharmaceuticals

Drug Profile

Lidocaine vaginal gel - Juniper Pharmaceuticals

Alternative Names: 10% lidocaine gel - Juniper Pharmaceuticals; COL-1077

Latest Information Update: 22 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Columbia Laboratories
  • Developer Columbia Laboratories; Juniper Pharmaceuticals
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Cell membrane permeability inhibitors; Opioid receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Discontinued Dysmenorrhoea; Pain

Most Recent Events

  • 17 Aug 2016 Discontinued - Phase-II for Pain in USA (Vaginal)
  • 01 Jul 2016 Juniper Pharmaceuticals completes a phase II trial for Pain in USA (NCT02465320)
  • 16 Jun 2016 Pharmacokinetic and adverse events data from pharmacokinetic trials in healthy women volunteers released by Juniper Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top